Complete Biochemical (Prostate-specific Antigen) Response to Sipuleucel-T With Enzalutamide in Castration-resistant Prostate Cancer: A Case Report With Implications for Future Research
Conclusion: Sipuleucel-T typically does not produce significant PSA reductions, and, to the best of our knowledge, only 1 previous report of a durable complete PSA response in a patient with metastatic disease has been published. The timing of this response supports an immune mechanism. The biologic rationale for the combination, coupled with the clinical result observed in our patient, provides a basis for studies of the combination of sipuleucel-T and enzalutamide.
Source: Urology - Category: Urology & Nephrology Authors: Julie N. Graff, Charles G. Drake, Tomasz M. Beer Tags: Medical Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | PET Scan | Prostate Cancer | Study | Urology & Nephrology